Introduction
============

Hepatitis C virus (HCV) infection is a major public health concern and a leading cause of liver-related morbidity and mortality globally \[[@r1]\]. There are an estimated 5.6 million people (1.1% of the population) living with chronic HCV infection in the World Health Organization European region \[[@r2]\]. In Europe, injecting drug use (IDU) is the major driver of this blood-borne infectious disease \[[@r3]-[@r5]\].

It is accepted that people who inject drugs (PWID) and HCV infection are typically over-represented in prison populations across Europe \[[@r6],[@r7]\]. A recently published meta-analysis reported a prison HCV prevalence in Western Europe of 15.5% (95% confidence interval (CI): 12.2--19.1), with this prevalence increasing to over 40% among those prisoners with a history of IDU \[[@r8]\]. Although prisoners have been identified as a key at-risk group for HCV infection, epidemiological data on the extent of the HCV burden in prisons is incomplete, out of date and, in some European countries, non-existent \[[@r6],[@r9]\]. Most epidemiological studies in people who inject drugs (PWID) and prisoners report on HCV antibody prevalence (exposure) and not presence of HCV RNA \[[@r6],[@r10],[@r11]\]. Where HCV RNA prevalence is reported, it is often on subsets of prisoners, and published studies do not differentiate between treated chronic infection with sustained viral response (SVR) and the 20--30% of HCV-infected people who spontaneously clear HCV without treatment \[[@r12]\].

Of the 600,000 people incarcerated in the European Union and European Economic Area (EU/EEA) at any given time, 3,400 are in prisons in Ireland \[[@r13]\]. A study in the year 2000 estimated the prevalence of HCV infection in the Irish prison population at 37%, increasing to 81% among those with a history of IDU \[[@r14]\]. A later study in 2014 reported an HCV prevalence of 13% \[[@r10]\]. This reducing trend in these two similar national studies is in keeping with a recognised global reduction in the prison prevalence of HCV and may in part be due to the expansion of community- and prison-based harm reduction services in Ireland \[[@r6],[@r10]\].There is no systematic approach to HCV screening in Irish prisons and only three Irish prisons (including the study location) have specialist in-reach hepatology services. No acute HCV infection has been diagnosed at the study site in the past decade. Despite national and international guidelines recommending HCV screening for all prisoners and a community equivalence of care in relation to HCV treatment access, most Irish prisoners are not screened or treated for HCV infection \[[@r15]-[@r17]\].

This study aimed to estimate the levels of untreated chronic HCV infection and associated risk factors for acquisition in an Irish prison population. It updates previous prevalence studies and is unique both nationally and internationally in reporting genotype distribution and estimating levels of untreated chronic infection in a prison population.

Methods
=======

This study is reported in accordance with the Strengthening the Reporting of Observational studies in Epidemiology guidance (STROBE) \[[@r18]\]. Ethical approval for the research was granted by The Mater Misericordiae University Hospital Research Ethics Committee (Ref:1/378/1839) and the Irish Prison Service (IPS) Ethics Review Committee.

The Irish Prison Service (IPS) partnered with the European Commission Third Health Programme-funded HepCare Europe project \[[@r19]\] to enhance screening for populations at risk of HCV infection and specifically implement an enhanced HCV screening programme at Mountjoy Prison in Dublin, Ireland. Mountjoy Prison is a large urban prison which at capacity houses 538 sentenced male prisoners. The mean age of prisoners incarcerated at this location is 34 years, with a third serving sentences of less than 12 months and almost half on restricted regimes (protection prisoners) \[[@r13],[@r20]\].

The programme consisted of an initial nurse-led screening programme followed by a peer-supported mass screening initiative. The Irish Red Cross trains a network of prison volunteers in basic community and public health across the IPS. Volunteers incarcerated at the study location collaborated in the design and implementation of this initiative which began in early 2017 and because of staffing and logistical issues required a 6-month period to complete.

All prisoners were offered screening for blood-borne viruses, including reflex RNA testing and genotyping. Reflex RNA testing is the automatic RNA testing of HCV antibody-positive samples without the need for a further request or repeat blood test.

Laboratory tests
----------------

First-line serological screening for hepatitis B virus (HBV), HCV and human immunodeficiency virus (HIV) was carried out using chemiluminescent microparticle immunoassays on the Architect i4000sr automated platform (Abbott, Chicago, United States). Confirmatory testing of reactive samples was carried out using alternative assays. HIV serological diagnosis was based on the Architect HIV Ag/Ab Combo (Abbott, Chicago, United States) and confirmatory testing for reactive samples using the VIDAS HIV DUO Ultra (BioMérieux, Marcy-l\'Étoile, France) and HIV INNO-LIA HIV I/II Score (Innogenetics, Ghent, Belgium ) assays. The Abbott Architect assays were used for HBV-associated markers and to characterise the HBV infection status. Serological screening for HCV included the anti-HCV test (Abbott Architect), a third-generation immunoassay and the Abbott Architect HCV Ag assay. All anti-HCV reactive samples negative for HCV antigen were further investigated to confirm the presence of anti-HCV antibodies using the anti-HCV VIDAS (BioMérieux) and INNO-LIA HCV Score (Innogenetics) assays. When HCV was confirmed serologically, molecular detection of HCV RNA was performed using the Abbott RealTi*me* HCV assay. HCV genotyping was conducted on samples with detectable HCV RNA using the Abbott RealTi*me* HCV Genotype II assay.

For this study, SVR was defined as HCV RNA-negative status at 24 weeks after completion of interferon-based treatment and 12 weeks for direct-acting antiviral (DAA) treatment. Chronic HCV infection was defined as ongoing active infection (HCV RNA-positive) 6 months or more after initial exposure (self-reported data from prisoners' electronic medical records stored in the Prison Health Management System (PHMS)). A review of historical serology and HCV risk history stored in the PHMS was conducted for prisoners testing HCV antibody-positive. This allowed the HCV serology to be interpreted as infection with self-clearance, infection with SVR or untreated chronic infection. This information was cross-checked with the prisoner for accuracy.

Data collection and analysis
----------------------------

Data on variables were collected from two sources; prisoners' electronic medical records stored in the PHMS and a researcher-administered questionnaire ([Supplement 1](file:///C:\\\\content\\\\10.2807\\\\1560-7917.ES.2019.24.14.1800369#supplementary_data)). All prisoners routinely complete a nurse committal interview on the day of incarceration which is stored in the prisoners' medical records in the PHMS. From this medical review, we collected the following variables: age, country of origin, history of drug and alcohol use, presence of visible injecting marks and history of sharing needles.

The questionnaire was developed and piloted by the research team in conjunction with national experts in the area of HCV infection and prisoner groups. The questionnaire included questions on age, country of origin, incarceration history, pre-incarceration accommodation, drug use, IDU history including history of sharing needles and drug-taking paraphernalia, history of tattooing, sharing of toothbrushes and razors while incarcerated and self-declared risk of HCV infection. Questionnaires were completed as part of screening but priority was given to screening, particularly in areas of the prison that housed enhanced-security prisoners.

All prisoners incarcerated on 31 March 2017 were eligible for inclusion in the study except those undergoing active treatment for severe mental illness and prisoners considered to pose a security risk to the research team. All study participants were given a patient information sheet and asked to sign a consent form. No inducements were offered.

All data were anonymised and coded, double-entered and checked. Statistical analysis was performed using the Statistical Package for Social Sciences (version 23.0; SPSS UK Ltd.; Chersey, United Kingdom). Data were assessed for normality and where necessary, data were log-transformed for normalisation purposes. Data in tables are primarily expressed as means with standard deviation (SD) or numbers with percentages. Categorical variables were assessed by chi-squared analysis (or Fisher's exact test for n \< 6) while nominal variables were assessed by independent t-test. Linear regression analysis adjusted for a history of IDU was used to identify possible risk factors for HCV infection (all variables initially selected, but then only the variables that resulted in the best model fit (R^2^) were left in the final model.

Results
=======

Demographic data
----------------

A total of 538 men were incarcerated on the day of the study, of whom 13 were excluded on mental health grounds, 58 refused consent to participate, 24 were released and 21 transferred to another prison before engagement in the study. A total of 422 (78.0% of the eligible population) participated in the study ([Figure](#f1){ref-type="fig"}). Committal interview data was available for all 422 participants, 404 (95.7% of study participants) completed screening, and 298 (73.8% of those screened) completed some or the entire risk questionnaire ([Figure](#f1){ref-type="fig"}).
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The median age of the study population was 33.3 years (range: 18--63), 394 (93.4%) were Irish and the remainder came from numerous other countries. There were no statistical differences for age and country of origin between the entire prison population and the study recruits. At the nurse committal interview (n = 422), 208 (49.3%) admitted to a history of drug use, 27 (6.4%) had visible active injecting sites and 30 (7.1%) reported a history of sharing needles.

Data from the questionnaire ([Table 1](#t1){ref-type="table"}) showed a mean age at first incarceration of 19.6 years, with the mean number of incarcerations being 5.9 and a total mean time spent in prison of 8 years. The mean age at first drug use, heroin use and IDU was 15.3 years, 19.5 years and 20.5 years, respectively. Of those prisoners who completed questions on HCV risk factors, 134 (46.7%) indicated a history of heroin use and 90 (32.6%) a history of IDU, 44 (15.9%) admitted to sharing needles and 104 (37.4%) to sharing drug-taking paraphernalia. In addition, 48 reported getting a tattoo in prison (16.5%) and 46 a non-sterile tattoo in the community (16.0%). Only 10 prisoners (3.4%) reported sharing razors and three (1%) a toothbrush. Overall 96 prisoners (34.7%) reported ever engaging with methadone maintenance treatment (MMT), with the mean length of time on treatment being 6.2 years ([Table 1](#t1){ref-type="table"}).

###### Demographic data of study participants, hepatitis C seroprevalence, Mountjoy Prison, Ireland, 31 March 2017--31 August 2017 (n = 422)

  Variable                                            Participants                             
  --------------------------------------------------- -------------- ------------ ------------ ------------
  Age (years)                                                                                  
  18--24                                              422            68           16.1         33.3 (8.7)
  25--34                                              203            48.1                      
  ≥ 35                                                151            35.8                      
  Age at first incarceration (years)                  298                         19.6 (6.8)   
  Episodes of incarceration                           294            5.9 (6.6)                 
  Total time incarcerated (years)                     293            8.0 (6.8)                 
  Age at first drug use (years)                       233            15.3 (8.2)                
  Age at first heroin use (years)                     202            19.5 (6.0)                
  Age at first injecting drug use (years)             86             20.5 (5.2)                
  Previous drug use^a^                                422            208          49.3         
  Visible injection site^a^                           422            27           6.4          
  Shared needles^a^                                   422            30           7.1          
  Place of origin                                                                              
  Ireland                                             422            394          93.4         
  Western Europe                                      4              0.9                       
  Eastern Europe                                      17             4.0                       
  Africa                                              7              1.7                       
  Accommodation before incarceration                                                           
  Secure                                              258            210          81.4         
  Homeless                                            48             18.6                      
  Risk factors for HCV acquisition                                                             
  History of heroin use                               287            134          46.7         
  History of injecting drug use                       276            90           32.6         
  Shared needle in the community                      277            44           15.9         
  Shared drug-taking equipment in the community       278            104          37.4         
  Shared razor in prison                              291            10           3.4          
  Shared toothbrush in prison                         292            3            1.0          
  Prison tattoo                                       291            48           16.5         
  Unsterile community tattoo                          287            46           16.0         
  Alcohol use                                                                                  
  Alcohol problem before incarceration                293            50           17.1         
  Treatment for alcohol use                           196            18           9.2          
  Methadone maintenance treatment                                                              
  History of methadone treatment                      277            96           34.7         
  Length of time on methadone maintenance treatment   96                          6.2 (5.8)    

HCV: hepatitis C virus; SD: standard deviation.

Values are means (± SD) for continuous variables or n (%) for categorical variables.

^a^ Data from committal interview.

### Blood-borne virus status

Of the 422 study participants, 404 (95.7%) had a screen for HIV and 403 (95.5%) each for HBV and HCV infection, with respective prevalences of 4.0%, 3.0% and 23.8%. Of the 92 HCV antibody-positive prisoners, 10 (11%) were co-infected with HIV and 6 (6.5%) with HBV. Prisoners with a history of IDU had an HCV antibody prevalence of 79.7%.

Among the HCV antibody-positive prisoners, 23 (25.0%) had spontaneous clearance, 16 (17.4%) had an SVR after treatment and the remaining 53 (57.6) had untreated chronic infection. This reflects an untreated chronic HCV infection prevalence of 13.2% among the 403 tested participants ([Table 2](#t2){ref-type="table"}).

###### Blood-borne virus screening results of study participants, Mountjoy Prison, Ireland, 31 March 2017--31 August 2017 (n = 404)

  Variable                                 Participants          
  ---------------------------------------- -------------- ------ ------
  HIV antibody                                                   
  Positive                                 404            16     4.0
  Negative                                 388            96.0   
  HBV antibody                                                   
  Positive                                 403            12     3.0
  Negative                                 391            97.0   
  HCV antibody                                                   
  Positive                                 403            92     22.8
  Negative                                 311            77.2   
  Reflex RNA testing                                             
  Positive (untreated chronic infection)   92             53     57.6
  Negative                                 39             42.4   
  SVR post treatment                       23             25.0   
  Spontaneous clearance                    16             17.4   
  Genotype                                                       
  1a                                       63             37     58.7
  3                                        26             41.3   

HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; SVR: sustained viral response.

Genotyping was available for 63 (50 from screening and 13 from medical records) of those with chronic infection (treated and untreated); 37 were infected with Genotype 1A and 26 with Genotype 3 ([Table 1](#t1){ref-type="table"}).

### Associations for hepatitis C virus infection

On comparative analysis (combined from committal interview and questionnaire) there were significant differences between those who were HCV antibody-positive and those who were not ([Table 3](#t3){ref-type="table"}). HCV antibody-positive prisoners were older (p \< 0.0001), had more episodes of incarceration (p \< 0.0001), had spent longer in prison (p \< 0.0001) and were younger at first heroin use (p = 0.0003) and IDU (p = 0.015). Stability of accommodation before incarceration was a factor for HCV status, with those experiencing homelessness more likely to be infected (p = 0.001). Country of origin did not impact on HCV status, with no statistical differences seen between Irish and non-Irish prisoners (p = 0.593). We could not examine the association with shared razors or toothbrushes in prison because of the small numbers.

###### Predictors of hepatitis C virus antibody status in study participants, Mountjoy Prison, Ireland, 31 March 2017--31 August 2017 (n = 403)

  Category                                        Variable                                    Positive     Negative     p value              
  ----------------------------------------------- ------------------------------------------- ------------ ------------ --------- ---------- ----------
  Age in years (SD)                               39.3 (6.9)                                  31.4 (8.4)   \<0.0001                          
  Place of origin (C)                             Ireland                                     85           92.3         290       93.2       0.593
  Western Europe                                  1                                           1.1          3            1                    
  Eastern Europe                                  3                                           3.3          14           4.5                  
  Africa                                          3                                           3.3          4            1.3                  
  Incarceration history (C)                       Age at first incarceration, in years (SD)   18.2 (6.5)   20(6.9)      0.067                
  Episodes of incarceration                       9.6                                         9.1          4.8          5.5       \<0.0001   
  Total time incarcerated, in years (SD)          12.6 (7.8)                                  6.5 (5.6)    \<0.0001                          
  Accommodation before incarceration (Q)          Secure                                      35           66           166       85.6       0.001
  Homeless                                        18                                          34           28           14.4                 
  Drug history (C)                                Previous drug use (yes)                     78           85.7         122       39.2       \<0.0001
  Visible injection site (yes)                    16                                          17.6         10           3.2       \<0.0001   
  Shared needles (yes)                            23                                          25.3         6            1.9       \<0.0001   
  History of alcohol use (yes)                    16                                          17.6         29           9.3       0.028      
  Drug history (Q)                                Age at first drug use in years (SD)         15.1 (4.4)   14.9 (4.9)   0.733                
  Age at first heroin use in years (SD)           17.7 (4.5)                                  20.7 (6.7)   0.003                             
  Age at first injecting drug use in years (SD)   19.3 (4.9)                                  22.1 (5.2)   0.015                             
  Time on MMT in years (SD)                       8 (8.0)                                     3.5 (4.4)    0.005                             
  History of drug use (yes)                       58                                          96.7         175          79.2      0.001      
  History of heroin use (yes)                     52                                          91.2         76           35.3      \<0.0001   
  History of injecting drug use (yes)             47                                          79.7         41           20.3      \<0.0001   
  Alcohol problem before incarceration (yes)      13                                          22           35           16        0.275      
  Treatment for alcohol use (yes)                 4                                           11.4         14           9.1       0.671      
  MMT history                                     45                                          81.8         47           22.7      \<0.0001   
  Reported HCV risk (Q)                           Shared needle in community                  32           55.2         11        5.4        \<0.0001
  Shared drug-taking equipment in community       42                                          73.7         54           26.2      \<0.0001   
  Prison tattoo                                   19                                          32.8         27           12.4      \<0.0001   
  Unsterile tattoo in community                   15                                          25.9         29           13.6      0.024      
  Shared razor in prison                          2                                           3.4          7            3.2       N/A        
  Shared toothbrush in prison                     1                                           1.7          1            0.5       N/A        
  Blood-borne virus results                       HIV antibody result                                                                        
  Positive                                        10                                          11           6            1.9       \<0.0001   
  Negative                                        81                                          89           303          98.1                 
  HBV antibody result                                                                                                                        
  Positive                                        6                                           6.6          6            1.9       0.023      
  Negative                                        85                                          93.4         302          98.1                 

C: committal interview; HBV: hepatitis B virus; HCV: hepatitis C virus; HIV: human immunodeficiency virus; MMT: methadone maintenance treatment; N/A: not applicable; Q: questionnaire; SD: standard deviation.

Values are means (±SD) for continuous variables or n (%) for categorical variables. Denominators for each variable represent participants for whom data was available. Student's independent t test was used to test differences between continuous variables. Chi-square tests were used to test differences between categorical variables.

HCV antibody-positive prisoners were significantly more likely to have a history of drug use (p = 0.001) or of heroin use, IDU or sharing needles or drug-taking paraphernalia in the community (p \< 0.0001). HCV antibody-positive prisoners were more likely to have had a prison tattoo (p \< 0.0001) and an unsterile community tattoo (p = 0.024). A pre-incarceration history of, and treatment for, alcohol misuse problems did not impact on prisoners' HCV status (p = 0.275 and p = 0.671, respectively). HCV antibody-positive prisoners were also significantly more likely to have a history of MMT (p \< 0.0001).

On preliminary multivariable analysis (including IDU), none of the above risk factors were independent risk factors for HCV infection ([Supplement 2](file:///C:\\\\content\\\\10.2807\\\\1560-7917.ES.2019.24.14.1800369#supplementary_data)). When IDU was excluded, only getting a non-sterile tattoo in the community remained an independent risk factor (p = 0.005) ([Table 4](#t4){ref-type="table"}).

###### Regression model, hepatitis C study, Mountjoy Prison, Ireland, 31 March 2017--31 August 2017 (n = 403 with all variables of interest)

                                                  B        SE B    β        *t*      p value
  ----------------------------------------------- -------- ------- -------- -------- ---------
  Constant                                        1.188    0.33    N/A      3.599    0.001
  Shared drug-taking equipment in the community   0.023    0.097   0.035    0.231    0.818
  Prison tattoo                                   −0.047   0.139   −0.052   −0.34    0.736
  Unsterile community tattoo                      0.468    0.157   0.468    2.977    0.005
  Homelessness                                    −0.075   0.082   −0.13    −0.922   0.362

B: beta; β: standardised version of B; HCV: hepatitis C virus; N/A: not applicable; SE B: standard error of B; t: t-statistic dependent variable: HCV antibody result.

Discussion
==========

This study found an HCV antibody prevalence of 22.8% in the general prison population of an Irish male prison, increasing to 79% among prisoners with a history of IDU. A quarter of the HCV-exposed cohort had spontaneously cleared the virus and 17.4% had an SVR post-treatment. Reflex RNA testing showed that 57.3% of HCV exposed prisoners had untreated chronic infection, which represents a prevalence of 13.1% untreated chronic HCV infection in the general prison population. The main risk for HCV acquisition was IDU (p \< 0.0001). This study found low levels of self-reported sharing of tooth brushes and razors.

The HCV antibody prevalence of 22.8% in this study is comparable to that reported in a review estimating the prevalence among prisoners globally \[[@r6]\]. It is higher than the 13% reported in the last Irish prison-based HCV prevalence study in 2014 \[[@r10]\] but lower than the 37% reported in an earlier study in 2000 \[[@r14]\]. Both these studies were multi-site national studies which included most of the 15 prisons in Ireland. The downward trend after the study in 2000 \[[@r14]\] is supported by the findings of the global 2013 systematic review \[[@r6]\] and a more recent European review which found that older studies reported higher prevalence rates \[[@r3]\].

The upward trend since the 2014 study may be explained by the fact that ours was a single-site study, in a prison considered to have moderate to high levels of PWID among its prison population and that consequently would be expected to have a higher HCV disease burden \[[@r6],[@r10],[@r14]\]. This finding also underpins the inter-prison and regional variation in HCV prevalence that occurs within and between countries and the need for accurate and institution-specific data when planning and resourcing prison-based HCV treatment services \[[@r6],[@r10],[@r14]\]. The HCV prevalence we estimated here reflects a rate 50 times higher than the estimated HCV prevalence in the general Irish population \[[@r21]\].

There is marked regional variation and extensive gaps in the data on the active HCV disease burden in prisoners \[[@r6]\]. Most prison-based prevalence studies report on HCV exposure rather than active infection \[[@r6],[@r10]\]. Of those exposed, 20--30% will spontaneously clear the virus and the remainder will progress to chronic infection, which is measured by the presence of HCV RNA in the blood 6 months after the acute infection \[[@r22]\]. Our study found a spontaneous clearance of 25%, similar to previously published studies \[[@r1],[@r22],[@r23]\].

We found that 23.2% of those with chronic infection had been successfully treated with SVR and not had re-infections to date. This level of treatment is high compared with other reported studies and may reflect the impact of an in-reach hepatology service at this site for many years \[[@r24],[@r25]\]. This finding also supports the existing evidence that PWID and prisoners can be successfully treated for HCV infection \[[@r26],[@r27]\]. The absence of re-infection among those showing SVR after treatment is contrary to published evidence showing high levels of re-infection among prisoners \[[@r28]\]. This may in part be due to the high levels of methadone maintenance treatment in Irish prisons. A study in Scotland reported that incarceration was protective against HCV transmission because of the high levels of opioid substitution treatment coverage in Scottish prisons \[[@r29]\].

In the era of interferon-based HCV treatment, so few PWID and prisoners were treated that HCV antibody prevalence data, mathematically modelled to allow for spontaneous clearance, reflected the untreated chronic HCV disease burden \[[@r6]\]. With the new DAA, therapies many countries are engaging significant numbers of prisoners and PWID in treatment with high compliance and SVR rates \[[@r30]-[@r32]\] Studies that report on HCV antibody levels in populations do not distinguish between self-clearance and SVR post treatment \[[@r12],[@r33]\] and miss the impact of treatment and rates of re-infection \[[@r12],[@r33]\]. This unique study demonstrates how more detailed HCV surveillance data can more accurately estimate the HCV disease burden in a population.

As previously outlined, drug users and PWID are over-represented in prison populations globally \[[@r6],[@r10]\]). This study reports similar findings with half of prisoners admitting to drug use and a third to a history of IDU. In this prison cohort, drug use began at an early age, with progression to heroin use and IDU within 5 years. High levels of risk behaviour related to drug use were also reported, including sharing needles and other drug-taking paraphernalia. These findings reflect the reality of drug use and risk behaviour in this marginalised cohort and indicate that prevention strategies are needed from a very young age.

A number of HCV transmission risks in prisoners have already been reported in the literature; these include IDU, prison tattooing and factors independent of these but linked to incarceration, such as violent assault, sharing of toothbrushes and razors \[[@r6],[@r10],[@r34],[@r35]\]. Our study reports IDU as being the main risk factor for HCV infection. A number of other variables (age, homelessness, length of time on methadone, length of time and numbers of times incarcerated, sharing of non-needle drug-taking paraphernalia and prison tattooing) were statistically associated with HCV exposure but in multivariable regression analysis not independent of IDU. This suggests that prisoners with a history of IDU have multiple HCV risks and that any planned HCV prevention strategies will need to target all these factors \[[@r6],[@r34],[@r36],[@r37]\].

Targeting prisoners with a history of IDU for active HCV case finding is a priority given the high HCV prevalence rates in this group \[[@r7]\]. It is also important to recognise that prisoners will under-report IDU because of fear of stigma and discrimination \[[@r6],[@r10],[@r12]\]. The move away from risk-based to opt-out prison-based HCV screening is addressing this issue in some jurisdictions and has the potential to be adapted by the IPS to increase screening uptake among Irish prisoners \[[@r38],[@r39]\].

Being older has previously been reported as a risk factor for past HCV infection \[[@r6],[@r10],[@r35]\]. We report similar findings for age but found that this was not independent of IDU. Again, this is expected given that older prisoners have longer histories of IDU with an elevated risk of potential HCV exposure over time. The finding that the vast majority of prisoners do not share toothbrushes or razors is encouraging and certainly in this particular prison eliminates these as sources of HCV transmission. Previous studies have reported high HCV prevalence among prisoners coming from countries of high HCV endemicity \[[@r6],[@r34],[@r40]\]. This study shows that being non-Irish in this prison population was not associated with HCV exposure. However, the numbers for this were small and had to be categorised for reporting in a way that protected anonymity.

The 78% participation is a major strength of this study. Previous Irish HCV prevalence studies found the prisoners in this particular prison difficult to engage and had much poorer uptake \[[@r10]\]. The use of prison-based peer workers in this study may account for the improved uptake. These studies were randomised in design and did not include the entire population. The use of serum samples rather than historical blood-borne virus screening data from chart records is unusual in these types of studies and with high levels of both sensitivity and specificity for this method offers increased validity to this study over those using saliva samples \[[@r10],[@r14]\].

The use of a research-completed questionnaire has both strengths and limitations. The researchers completing the questionnaire were unknown to the prisoners which may have allowed for more frank disclosure of risk behaviour. The two previous Irish studies used self-completed questionnaires. The design of our study allowed researchers to spend time with the prisoner and to add clarification regarding the meaning/interpretation of the questions. While overcoming the issue of literacy, it was time-consuming which impacted on completion rates.

There are a number of limitations to this study. It was single-site and only included male prisoners, making the findings more difficult to generalise both nationally and internationally. The study was designed to allow for its implementation in a real prison setting and for it to be both a health intervention (HCV screening) and a research study measuring HCV prevalence. The dynamic nature of prison populations (releases, inter-prison transfers and short sentences) makes cross-sectional epidemiological studies difficult to implement. In addition, owing to the nature of the study we did have a small 'n' for a number of variables of interest. Where statistically possible, we tried to keep important variables in statistical models and we did utilise tests for normality for small sizes and test model quality. However caution must be used in the interpretation of the results until they are replicated in larger studies.

The self-reported nature of the data is a limitation. We did not receive ethical approval to retrieve data on study participants' incarceration history from their electronic prison records and therefore had to rely on self-reporting for these variables which may be prone to bias. There were limits on allocated time to access prisoners; consequently, screening was prioritised over the completion of the risk questionnaire. This was particularly an issue with protection prisoners where enhanced security measures were in place.

Conclusion
==========

This study reports an anti-HCV prevalence of 22.8%, with an untreated chronic HCV prevalence of 13.2% in a male Irish prison population. The identified genotype distribution was 58% genotype 1A and 42% genotype 3A. The main risk for HCV infection was IDU but there was also a statistically significant association with prison tattooing, non-sterile community tattooing, the sharing of needles and other drug-taking paraphernalia, older age and pre-incarceration homelessness. The sharing of toothbrushes and razors or not having Ireland as a country of origin were not associated with HCV exposure. The reporting of HCV infection in prisoners in this way is unique in both the Irish and international literature and allows for the estimation of the true levels of active HCV infection, the monitoring of treatment outcomes and rates of re-infection. Identifying risk factors for HCV infection allows for targeted prevention, screening and treatment strategies. Combined, they allow informed planning and implementation of national and international HCV strategies.

The authors would like to acknowledge the support of the Hepcare Europe team at the Mater Misericordiae Hospital and University College Dublin, and the staff and the management of the Irish Prison Service. The authors would also like to thank the prisoners who participated in the study.

This study was partially funded by AbbVie.

**Conflict of interest:** None declared.

**Authors' contributions:** Desmond Crowley, John S. Lambert, Graham Betts-Symonds, Walter Cullen, Mary Keevans, Enda Kelly, Tina McHugh, Susan McKiernan, Carol Murphy, Deirdre O\'Reilly and Marie Claire Van Hout were involved in the design and planning of the study.

Desmond Crowley, Graham Betts-Symonds, Mary Keevans, Tina McHugh, Sarah Jayne Miggin and Carol Murphy were responsible for the implementation of the study.

Fieldwork, screening and data collection was completed by Desmond Crowley, Graham Betts-Symonds, Walter Cullen, Mary Keevans, Tina McHugh, Sarah Jayne Miggin, Carol Murphy, Ross Murtagh, Deirdre O\'Reilly and Ciara Tobin.

Desmond Crowley, John S. Lambert, Walter Cullen, Eamon Laird and Ross Murtagh were responsible for interpretation and analysis.

Desmond Crowley was responsible for drafting the manuscript.

Desmond Crowley, John S. Lambert, Graham Betts-Symonds, Walter Cullen, Mary Keevans, Enda Kelly, Eamon Laird, Tina McHugh, Susan McKiernan, Sarah Jayne Miggin, Carol Murphy, Ross Murtagh, Deirdre O\'Reilly, Ciara Tobin and Marie Claire Van Hout contributed critical revision and approval of the final manuscript.

453000

###### Supplement1

###### 

Click here for additional data file.

91000

###### Supplement2

###### 

Click here for additional data file.

[^1]: Correspondence: Desmond Crowley (<des.crowley@icgp.ie>)
